Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Novartis (NVS - Snapshot Report) recently announced that data on its pipeline candidate RLX030 was published in the European Heart Journal and also presented at the European Society of Cardiology (ESC) congress.

Data from the phase III study (RELAX-AHF) revealed that treatment with RLX030 improved symptoms and mortality rates across multiple subgroups of patients suffering from acute heart failure (AHF).

Further, the addition of RLX030 to conventional treatment led to improvements in breathlessness and mortality at 6 months across all pre-specified subgroups.

Novartis is developing RLX030 for the treatment of AHF.

We note that RLX030 is currently under review in several countries including the U.S. and the EU.

In Jun 2013, the U.S. Food and Drug Administration (FDA) granted “Breakthrough Therapy” designation to RLX030. The designation should help fasten the development and review process of the candidate.

As per Novartis, as many as 3.5 million AHF incidents take place in the U.S. and EU annually. The incidents are expected to go up further as the population ages.

We note that Novartis had another candidate LCZ696, which is in phase III development, for the treatment of chronic heart failure.

We are encouraged by the pipeline progress at Novartis. In Aug 2013, Novartis obtained ‘Breakthrough Therapy’ designation from the FDA on another pipeline candidate, BYM338, for the sporadic inclusion body myositis indication.

Novartis currently carries a Zacks Rank #3 (Hold). Right now, Jazz Pharmaceuticals (JAZZ - Analyst Report), Ironwood Pharmaceuticals (IRWD - Analyst Report), and Forest Laboratories Inc. (FRX - Analyst Report) look attractive with a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%